TWD
TRDA icon

True Wealth Design’s Entrada Therapeutics TRDA Stock Holding History

True Wealth Design’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.44K Sell
226
-81
-26% -$562 ﹤0.01% 1805
2026
Q2 		$2.26K Buy
307
+283
+1,179% +$2.71K ﹤0.01% 1636
2026
Q1 		$303 Buy
24
+23
+2,300% +$264 ﹤0.01% 2214
2025
Q4 		$11 Hold
1
– – ﹤0.01% 2518
2025
Q3 		$6 Sell
1
-30
-97% -$176 ﹤0.01% 2704
2025
Q2 		$209 Buy
+31
New +$249 ﹤0.01% 2058
2025
Q1 		– Sell
-93
Closed -$1.61K – 2684
2024
Q4 		$1.61K Buy
+93
New +$1.69K ﹤0.01% 795

Other funds holding TRDA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

True Wealth Design's TRDA Position: Q3 2026 in Review

True Wealth Design reduced its Entrada Therapeutics (TRDA) stake by 26% in Q3 2026, selling an estimated $562 and leaving 226 shares worth $1.44K. The position accounts for ﹤0.01% of the portfolio, ranked #1805.

True Wealth Design first reported a position in TRDA in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.26K in Q2 2026. 8 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • True Wealth Design held 226 shares of Entrada Therapeutics worth $1.44K as of Q3 2026.
  • True Wealth Design sold 81 Entrada Therapeutics shares in Q3 2026, an estimated $562.
  • Entrada Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q3 2026, its #1805 holding.
  • True Wealth Design first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • True Wealth Design's Entrada Therapeutics position peaked at $2.26K in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.